Robertson S E, Suleiman A J, Mehta F R, al-Dhahry S H, el-Bualy M S
Global Programme for Vaccines and Immunization, World Health Organization, Geneva, Switzerland.
Bull World Health Organ. 1994;72(6):907-14.
Countries are increasingly requesting guidance on carrying out acute flaccid paralysis (AFP) surveillance, aimed at detecting and confirming all cases of acute paralytic poliomyelitis. The experience of Oman provides many lessons in this respect. AFP surveillance in Oman was established systematically. First, an epidemiologist was assigned to coordinate surveillance, and a laboratory for performing polio-virus isolation was identified. Next, operational guidelines for AFP surveillance were developed and widely promoted among health staff. The quality of the system has been monitored for more than 3 years with selected performance indicators. From January 1990 to April 1993, 49 AFP cases were reported, corresponding to an average annual rate of 2.1 AFP cases per 100,000 children aged less than 15 years. A total of 98% of the AFP cases were investigated within 48 hours of being reported; two stool samples were obtained from 94% of the cases. Following complete investigation, nearly a third of the reported AFP cases were classified as being clinically compatible with Guillain-Barré syndrome. Four AFP cases, all reported in 1991, were confirmed to be due to wild type 3 poliovirus. Because AFP surveillance detected these cases rapidly, Oman was able to carry out outbreak control measures promptly and more than 350,000 extra doses of oral poliovirus vaccine were delivered to children under 6 years of age.
各国越来越多地要求提供有关开展急性弛缓性麻痹(AFP)监测的指导,旨在发现并确认所有急性麻痹性脊髓灰质炎病例。阿曼的经验在这方面提供了许多教训。阿曼的AFP监测是系统建立的。首先,指定一名流行病学家协调监测工作,并确定了一个进行脊髓灰质炎病毒分离的实验室。其次,制定了AFP监测的操作指南,并在卫生工作人员中广泛推广。该系统的质量已通过选定的绩效指标进行了三年多的监测。1990年1月至1993年4月,报告了49例AFP病例,相当于每10万名15岁以下儿童中AFP病例的年平均发生率为2.1例。在报告的AFP病例中,98%在报告后48小时内接受了调查;94%的病例采集了两份粪便样本。经过全面调查,近三分之一的报告AFP病例被归类为临床符合吉兰-巴雷综合征。1991年报告的4例AFP病例被确认为由野生3型脊髓灰质炎病毒引起。由于AFP监测迅速发现了这些病例,阿曼得以迅速采取疫情控制措施,并向6岁以下儿童额外发放了超过35万剂口服脊髓灰质炎疫苗。